Literature DB >> 17058502

DNA vaccines: safety aspect assessment and regulation.

T D E Medjitna1, C Stadler, L Bruckner, C Griot, H P Ottiger.   

Abstract

For licensing purposes, besides the immunogenic aspects, deoxyribonucleic acid (DNA) vaccines present safety considerations that must be critically assessed during preclinical or/and clinical safety studies. The major concerns with regard to safety are integration of the plasmid DNA into the host genome, adverse immunopathological effects, the formation of anti-DNA antibodies resulting in auto-immune disease and the use of novel molecular adjuvants. Moreover, for veterinary vaccines intended to be used in husbandry animals, food safety aspects will become an important issue. All new vaccine candidates should therefore be thoroughly tested in target animals, keeping in mind that for food producing animals, the products will be consumed. Finally, a further safety aspect of interest concerns the possible spread of genetic material to the environment, by the potential transformation of the environmental microflora with only a few copies of complete or fragmented plasmid. These are issues that need to be considered in the final scientific decisions underpinning the registration of vaccines. Thus, to establish criteria for guidance and regulations for industry and licensing authorities, a project has been initiated to assess such risks of plasmid DNA vaccinations. Major emphasis will be placed on aspects such as the biodistribution of plasmid in vaccinated animals. This paper is intended as a contribution to the debate on the use of biotechnology in the future and should facilitate further discussions on the various safety aspects of DNA-based immunisations.

Mesh:

Substances:

Year:  2006        PMID: 17058502

Source DB:  PubMed          Journal:  Dev Biol (Basel)        ISSN: 1424-6074


  5 in total

1.  Vaccination with a codon-optimized A27L-containing plasmid decreases virus replication and dissemination after vaccinia virus challenge.

Authors:  Osmarie Martínez; Ariana Bravo Cruz; Saritza Santos; Maite Ramírez; Eric Miranda; Joanna Shisler; Miguel Otero
Journal:  Vaccine       Date:  2017-06-16       Impact factor: 3.641

2.  Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H pylori ureB and IL-2.

Authors:  Can Xu; Zhao-Shen Li; Yi-Qi Du; Yan-Fang Gong; Hua Yang; Bo Sun; Jing Jin
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

Review 3.  DNA vaccines: ready for prime time?

Authors:  Michele A Kutzler; David B Weiner
Journal:  Nat Rev Genet       Date:  2008-10       Impact factor: 53.242

4.  The efficacy, biodistribution and safety of an inhibin DNA vaccine delivered by attenuated Salmonella choleraesuis.

Authors:  Wei-Zhen Chen; Ying-Mei Li; Xue Yu; Yue Li; Wen-Ke Li; Qing-Ling Wang; Ai-Xin Liang; Xiang Li; Li-Guo Yang; Li Han
Journal:  Microb Biotechnol       Date:  2017-12-04       Impact factor: 5.813

Review 5.  Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review.

Authors:  Khatereh Asadi; Ahmad Gholami
Journal:  Int J Biol Macromol       Date:  2021-04-16       Impact factor: 6.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.